XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 19, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name Arcadia Biosciences, Inc.    
Entity Central Index Key 0001469443    
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Common Stock, Shares Outstanding   1,367,040  
Entity Public Float     $ 4,184,025
Stock price     $ 3.15
Entity Listing, Par Value Per Share $ 0.001    
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity Small Business true    
Entity File Number 001-37383    
Entity Tax Identification Number 81-0571538    
Entity Address, Address Line One 5950 Sherry Lane    
Entity Address, Address Line Two Suite 215    
Entity Address, City or Town Dallas    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 75225    
City Area Code 214    
Local Phone Number 974-8921    
Entity Incorporation, State or Country Code DE    
Trading Symbol RKDA    
Title of 12(b) Security Common    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Documents Incorporated by Reference

Information required by Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant's Definitive Proxy Statement for its 2025 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.

    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 34    
Auditor Name Deloitte & Touche LLP    
Auditor Location Tempe, AZ    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Arcadia Biosciences, Inc. and subsidiaries (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.